Ilypsa Appoints Samuel R. Saks, M.D. to Board of Directors.SANTA CLARA Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. , Calif. -- Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal and metabolic disorders, today announced that Samuel R. Saks, M.D., Chief Executive Officer, Jazz Pharmaceuticals, will be joining Ilypsa's Board of Directors. "I am personally delighted to welcome Sam to Ilypsa's Board. Sam's wealth of industry management, development and commercial expertise in start ups and mature pharmaceutical companies make him an excellent addition to Ilypsa's Board," said Jay Shepard, President and Chief Executive Officer of Ilypsa. "In my experience, it's rare to find industry experience so uniquely matched by product development track record and pharmaceutical portfolio strategy." "It is my pleasure to be joining Ilypsa's Board of Directors at a time when the company is advancing a promising pipeline and weighing a breadth of strategic and funding opportunities," said Dr. Saks. "Ilypsa is well positioned with strong management, an elegant drug discovery and development platform and a lead product moving into Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the . I am looking forward to working with the Board and management team in capitalizing on Ilypsa's exciting commercial opportunities." Prior to co-founding Jazz Pharmaceuticals, Dr. Saks most recently was company group chairman, and a member of the Johnson & Johnson Pharmaceutical Operating Committee at ALZA Corporation. During his nine years at ALZA, Dr. Saks held several executive positions including Group Vice President and Senior Vice President, Medical Affairs, and was responsible for manufacturing, preclinical and clinical research, regulatory, project management, new product discovery and sales and marketing. Prior to joining ALZA, Dr. Saks was Vice President, Clinical Research, Oncology at Schering-Plough and earlier at Xoma Corporation. Previously, he was Associate Director, Clinical Research at Genentech. Dr. Saks is currently a director of Jazz Pharmaceuticals, and Trubion Pharmaceuticals, and was previously a director at Ribozyme Ribozyme A ribonucleic acid (RNA) molecule that, like a protein, can catalyze specific biochemical reactions. Examples include self-splicing rRNA and RNase P, both involved in catalyzing RNA processing reactions (that is, the biochemical reactions that convert Pharmaceuticals (now Sirna Therapeutics Sirna Therapeutics Inc. (NYSE: RNAI), Sirna develops therapeutics based on RNA interference (RNAi) technology, a new and extremely potent method of using nucleic acids as drugs. ), Coulter Pharmaceutical and Corixa Corporation. Dr. Saks holds an M.D. degree from the University of Illinois University of Illinois may refer to:
About Ilypsa, Inc. Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a pipeline of next-generation renal care pharmaceutical products. Pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies Symyx Technologies NASDAQ: SMMX is a pioneer in the area of combinatorial chemistry applied to heterogeneous catalysis and homogeneous catalysis, polymer formulations, electronic and magnetic materials. , Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : SMMX), Ilypsa has rapidly created non-absorbed polymeric polymeric /poly·mer·ic/ (pol?i-mer´ik) exhibiting the characteristics of a polymer. pol·y·mer·ic adj. 1. Having the properties of a polymer. 2. phosphate and potassium binder compounds to treat chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is , and has additional programs in kidney, infectious and metabolic diseases. To date, Ilypsa has raised $46 million in a Series A and Series B round of financing. Investors include The Sprout Group, 5AM Ventures, US Venture Partners, Johnson & Johnson Development Corporation and Delphi Ventures. For more information, please visit www.ilypsa.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion